Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy

Abstract

Read online

This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.

Keywords

• Ductal carcinoma in situ
• tamoxifen
• aromatase inhibitor
• breast cancer
• hormonal
• adjuvant.